tirzepatide and hydroxychloroquine Obesity drug seen as effective for long COVID, gets clinical trial More evidence hints hydroxychloroquine doesn't

Based on the 2025 SURMOUNT-5 trial, Tirzepatide produced 20.2% body weight loss compared to 13.7% with Semaglutide over 72 weeks, along with a greater relative reduction in 10-year cardiovascular disease risk

Our program is designed for individuals who need more than just diet advice to see results

This is especially important if you have a compromised immune system or a serious underlying condition

Interim analysis An interim analysis was performed by an individual data monitoring committee, and the sponsor project members were kept blinded to the treatment assignments until individual trial data were locked

Ideal candidates are committed to a healthy lifestyle and realistic wellness goals

WHO found that in 2022: Over 2.5+ billion suffered from overweight problems